Long-term low-dose tolvaptan efficacy and safety in SIADH.
Marta BondanelliLudovica AlibertiIrene GagliardiMaria Rosaria AmbrosioMaria Chiara ZatelliPublished in: Endocrine (2023)
The present study shows that long-term low-dose Tolvaptan is safe and effective in SIADH treatment. No cases of overcorrection were documented and mild side effects were reported.